Evidence map›Paper›PMID 42362968›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.

Zoë C Cooper, Indira Garcia-Cordero, Maria Carmela Tartaglia, Adam M Staffaroni, Kevin Duff, Douglas Gunzler, Adam L Boxer, Anne-Marie Wills

2 registry-linked trialsAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02985879 phase2terminatednot on this map

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy

TypeinterventionalSponsorAbbVieRan2016 to 2019Enrolled378ConditionsProgressive Supranuclear PalsyArmsPlacebo, ABBV-8E12
NCT03068468 phase2terminatednot on this map

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

TypeinterventionalSponsorBiogenRan2017 to 2020Enrolled490ConditionsSupranuclear Palsy, ProgressiveArmsBIIB092, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zoë C CooperDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0000-6743-6085
Indira Garcia-CorderoCognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Adam M StaffaroniFein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Kevin DuffLayton Aging & Alzheimer's Disease Center, Oregon Health & Science University, Portland, Oregon, USA.
Douglas GunzlerPopulation Health and Equity Research Institute, Center for Health Care Research and Policy, MetroHealth Medical Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Adam L BoxerFein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Anne-Marie WillsDepartment of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.

Funding

U.S. Food and Drug Administration U18FD005320
6 · The paper itself

Abstract

introductionProgressive supranuclear palsy (PSP) causes executive dysfunction, fluency deficits, and behavioral changes. We examined longitudinal changes in PSP cognition using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).

methodsUsing the RBANS and executive function and fluency tests from 486 and 377 participants in the PASSPORT (NCT03068468) and tilavonemab (NCT02985879) clinical trials, we assessed linear mixed models of cognitive subtest score change, controlling for disease duration, age, sex, and treatment group.

resultsThe greatest declines occurred in subtests assessing visuospatial (figure copy, figure recall), executive function (Color Trails, coding), and fluency (primarily semantic fluency), although controlling for motor and ocular motor disability reduced the magnitude of score decline. Subtests assessing immediate and delayed memory (story recall, story memory, list recall, list recognition) declined slowly or not at all. DISCUSSION: Cognition in PSP is characterized by declines in executive, visuospatial function, and fluency, with relative preservation of memory.

Indexed as

CognitionSupranuclear Palsy, ProgressiveAgedExecutive FunctionFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological Testscognitioncognitive declineColor Trailsexecutive functionfluencymemoryprogressive supranuclear palsy (PSP)Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)visuospatial function

Identifiers

PMID42362968
PMCPMC13309287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.